China fine chemical Reuters on October 25, reporter from 14th Beijing international BBS bio-pharmaceutical industry development is told this three 100 billion biomedical project under construction in the city. On that day, the largest pharmaceutical companies -- China national pharmaceutical group (" drug group ") announced its health group and its subsidiaries in lanzhou, wuhan and changchun and other biological product 6 overall market has found.
Meanwhile, yunnan province public five seconds "period to develop biological medicine, and strive to hundreds of billions of scale.
Shanghai and Beijing also introduces their own biomedical brewing "second five-year" plan. Shanghai is the overall objective of 2012, reached the end of 2 billion yuan bio-pharmaceutical industry total economic output. To support 100 more than 200 million yuan in output value and innovative enterprise, establish sales of more than 100 million high-tech high-quality products; And Beijing try 3 years bio-pharmaceutical industry from size less than 400 million to current 100 billion yuan.
The second half by 2010, China's economic development, biomedical industries, such as emerging trends, quite Liaoyuanzhishi fire.
Flame was lit on October 18, the state council accelerate the development of new industries and development of strategic decision. "at this stage will be focused on cultivating and developing energy-saving and environmental protection, a new generation of information technology, biotechnology, and other seven new industrial, strategic and by 2015 GDP of emerging industry to reach 8%.
Biological medicine is a sunrise industry in the next 10 years, has no doubt. TCM transformation and technology center rui guozhong forecast, 2013 our country medicine market will become the world's third largest pharmaceutical market; Industry in Chinese medicine in 2020 will reach four trillion yuan size, more than Japan and Europe become the world's second largest pharmaceutical market. China's global positioning satellite in bio-pharmaceutical industry rising.
Shanghai and Beijing also introduces their own biomedical brewing "second five-year" plan. Shanghai is the overall objective of 2012, reached the end of 2 billion yuan bio-pharmaceutical industry total economic output. To support 100 more than 200 million yuan in output value and innovative enterprise, establish sales of more than 100 million high-tech high-quality products; And Beijing try 3 years bio-pharmaceutical industry from size less than 400 million to current 100 billion yuan.
The second half by 2010, China's economic development, biomedical industries, such as emerging trends, quite Liaoyuanzhishi fire.
Flame was lit on October 18, the state council accelerate the development of new industries and development of strategic decision. "at this stage will be focused on cultivating and developing energy-saving and environmental protection, a new generation of information technology, biotechnology, and other seven new industrial, strategic and by 2015 GDP of emerging industry to reach 8%.
Biological medicine is a sunrise industry in the next 10 years, has no doubt. TCM transformation and technology center rui guozhong forecast, 2013 our country medicine market will become the world's third largest pharmaceutical market; Industry in Chinese medicine in 2020 will reach four trillion yuan size, more than Japan and Europe become the world's second largest pharmaceutical market. China's global positioning satellite in bio-pharmaceutical industry rising.
Much good policies coming
Experts say: "2010-2015 bio-pharmaceutical industry promotion plan", diligently develops, but by the end of this year will be introduced. At this time, many support policies will focus on "DiErWuNian plan", is expected to be available in advance.
China biomedical industries is entering a policy on period. According to the red guozhong, "new medical reform policy from the macro expanded version full implementation of the basic medicine, the new GMP pharmaceutical production management (standard), 863 biological medicine, science and technology project of major new drugs, perfect the major infectious disease of the industry's" special "" drug registration", "new medical instrument regulations", "the Chinese medicine injection 689 new technology standards" and other policies, including biological medicine, centralized support policy, introduced in this year are expected. "Good policy" is not only more fierce, and concentrated, reconstruction of chain China biomedical industries. "
Center for pharmaceutical industry in China the confidence of the Shanghai securities news said ren Zhongqian, biological medicine "twelve 5" plan will be submitted to nine key projects, the first the development of biomedicine, to realize industry upgrading of traditional medicine, and provide financial support. Target "to promote upgrading the pharmaceutical industry, supporting policies will soon come out."
The new version of the GMP (the pharmaceutical industry standards for drugs) is currently the most talked about policy support. China pharmaceutical enterprise management association says, mathilda, pharmaceutical quality assurance system upgrade is the pharmaceutical industry is an important component of the overall upgrade. It is also a decision is based on safe and effective drugs. The modified version of the pharmaceutical production quality management, take already through the process and recent introduction expected."
Guizhou tells a reporter, the new version of the GMP have a three-year transition period is expired company standards, he also shall be ordered to stop production or for correcting. "GMP pharmaceutical company massive upgrade software requirements, it is China's next abdomen soft in the pharmaceutical industry."
In addition to drug standards, the product standard and new drugs in upgrade. "In the five-year plan, the country will have a series of concrete actions to promote medical product improvement standards. Including the traditional Chinese medicine, Chinese medicine injection, shenghua yao injection, including drug substances and drug products to control and residual solvents impurities, except for some new test items and methods. These change is bigger, can introduce some new product standards of modern medicine." In matilda said.
Meanwhile, in order to enhance the innovation ability, Shanghai securities news learned to use, and biomedical "second five-year" plan has also announced a new drug as a special "twelve five-year" plan. The development of innovative drug significant financial support the 11th five-year development scale expansion "period, 66 million 105 billion dollars. The first 300 years is expected to announce the winning project. Personal funds to support 100-10000000 drug development project scale from technology development platform, support scale from 1000 to 60 million. These policies will be" lure "enterprise increase r&d in addition, according to the Shanghai science and technology commission, deputy director of biomedical department contact zheng he tells a reporter, the legislative affairs office of the state council" currently in drug registration ", "medical instrument new management consulting activity" to clarify research institutions and between enterprise's industry positioning."
Experts say: "2010-2015 bio-pharmaceutical industry promotion plan", diligently develops, but by the end of this year will be introduced. At this time, many support policies will focus on "DiErWuNian plan", is expected to be available in advance.
China biomedical industries is entering a policy on period. According to the red guozhong, "new medical reform policy from the macro expanded version full implementation of the basic medicine, the new GMP pharmaceutical production management (standard), 863 biological medicine, science and technology project of major new drugs, perfect the major infectious disease of the industry's" special "" drug registration", "new medical instrument regulations", "the Chinese medicine injection 689 new technology standards" and other policies, including biological medicine, centralized support policy, introduced in this year are expected. "Good policy" is not only more fierce, and concentrated, reconstruction of chain China biomedical industries. "
Center for pharmaceutical industry in China the confidence of the Shanghai securities news said ren Zhongqian, biological medicine "twelve 5" plan will be submitted to nine key projects, the first the development of biomedicine, to realize industry upgrading of traditional medicine, and provide financial support. Target "to promote upgrading the pharmaceutical industry, supporting policies will soon come out."
The new version of the GMP (the pharmaceutical industry standards for drugs) is currently the most talked about policy support. China pharmaceutical enterprise management association says, mathilda, pharmaceutical quality assurance system upgrade is the pharmaceutical industry is an important component of the overall upgrade. It is also a decision is based on safe and effective drugs. The modified version of the pharmaceutical production quality management, take already through the process and recent introduction expected."
Guizhou tells a reporter, the new version of the GMP have a three-year transition period is expired company standards, he also shall be ordered to stop production or for correcting. "GMP pharmaceutical company massive upgrade software requirements, it is China's next abdomen soft in the pharmaceutical industry."
In addition to drug standards, the product standard and new drugs in upgrade. "In the five-year plan, the country will have a series of concrete actions to promote medical product improvement standards. Including the traditional Chinese medicine, Chinese medicine injection, shenghua yao injection, including drug substances and drug products to control and residual solvents impurities, except for some new test items and methods. These change is bigger, can introduce some new product standards of modern medicine." In matilda said.
Meanwhile, in order to enhance the innovation ability, Shanghai securities news learned to use, and biomedical "second five-year" plan has also announced a new drug as a special "twelve five-year" plan. The development of innovative drug significant financial support the 11th five-year development scale expansion "period, 66 million 105 billion dollars. The first 300 years is expected to announce the winning project. Personal funds to support 100-10000000 drug development project scale from technology development platform, support scale from 1000 to 60 million. These policies will be" lure "enterprise increase r&d in addition, according to the Shanghai science and technology commission, deputy director of biomedical department contact zheng he tells a reporter, the legislative affairs office of the state council" currently in drug registration ", "medical instrument new management consulting activity" to clarify research institutions and between enterprise's industry positioning."
High growth, high profit margins double temptation
Matilda said, "country, second five-year" plan to determine the focus of the development of biotechnology, including gene drugs, protein drugs, monoclonal antibodies cloning drugs, vaccines, small molecules drug therapy, this policy will actively promote Chinese biomedical bio-pharmaceutical industry's rapid development is expected.
Investment advisers in the pharmaceutical industry researchers GuoFanLi says to the reporter, China biomedical industries will be maintained a rapid growth, the future. "In 2009, China biomedical industries, total sales income reached henan billion yuan, so the pace of development make pharmaceutical industry is one of the fastest growing regions. Meanwhile, bio-pharmaceutical industry profit growth to 70 per cent, profits growth, high pace of development has become an emerging industry, biological medicine industry in one of the most striking object."
In the policy guidance and high - how many traditional Chinese herbal medicines, high growth, the company will change by biomedical company.
A production of western medicine API, pharmaceutical intermediates, designed for pharmaceutical companies listed on the main product manager when accepting a reporter to interview, the company plans to use 5 ~ 10 years, completely transformed into biological pharmaceutical company, invest heavily in r&d funds. He said: "I vaccine refining project r&d investment more than 8000 yuan, will go on sale, 2 years; the humanized monoclonal antibodies in anti-tumor necrosis factor in the project total investment of 100 million yuan."
Biomedical investment projects for the traditional pharmaceutical company has brought tangible and sustainable profit growth. Deputy general manager "yuan, according to health, currently USES the production cephalosporin biocatalytic jiaozuo middle class 7aca very successful, this project has become the most important and the fastest growing source of profit." We are for soybean, corn fermentation 7aca, environmental pollution, the current production capacity development. "
The New York stock exchange market successfully in the United States, China's largest high-tech medical equipment company - shenzhen Mindray biomedical electronic silver stakeholders to reporters, electronic medical equipment field of biological existence supporting industries, lack of technical standards, as well as foreign companies extrusion problems. He told reporters that can be expected, ten years biomedical industrial concentration is more and more, leading to large enterprises, government should provide better services, create public research and development platform and enhance competitiveness.
Now, government departments in biomedical industries have been aware of the important significance of local economic development, and have corresponding preferential policies.
According to the shenzhen trade and industry and information commission, to the reporter stakeholders, the city will be Internet, new energy and biological medicine and other emerging industry funds to the development of 10 billion us dollars. "Soon, the first batch of 35 biomedical support program will be agreed."
Matilda said, "country, second five-year" plan to determine the focus of the development of biotechnology, including gene drugs, protein drugs, monoclonal antibodies cloning drugs, vaccines, small molecules drug therapy, this policy will actively promote Chinese biomedical bio-pharmaceutical industry's rapid development is expected.
Investment advisers in the pharmaceutical industry researchers GuoFanLi says to the reporter, China biomedical industries will be maintained a rapid growth, the future. "In 2009, China biomedical industries, total sales income reached henan billion yuan, so the pace of development make pharmaceutical industry is one of the fastest growing regions. Meanwhile, bio-pharmaceutical industry profit growth to 70 per cent, profits growth, high pace of development has become an emerging industry, biological medicine industry in one of the most striking object."
In the policy guidance and high - how many traditional Chinese herbal medicines, high growth, the company will change by biomedical company.
A production of western medicine API, pharmaceutical intermediates, designed for pharmaceutical companies listed on the main product manager when accepting a reporter to interview, the company plans to use 5 ~ 10 years, completely transformed into biological pharmaceutical company, invest heavily in r&d funds. He said: "I vaccine refining project r&d investment more than 8000 yuan, will go on sale, 2 years; the humanized monoclonal antibodies in anti-tumor necrosis factor in the project total investment of 100 million yuan."
Biomedical investment projects for the traditional pharmaceutical company has brought tangible and sustainable profit growth. Deputy general manager "yuan, according to health, currently USES the production cephalosporin biocatalytic jiaozuo middle class 7aca very successful, this project has become the most important and the fastest growing source of profit." We are for soybean, corn fermentation 7aca, environmental pollution, the current production capacity development. "
The New York stock exchange market successfully in the United States, China's largest high-tech medical equipment company - shenzhen Mindray biomedical electronic silver stakeholders to reporters, electronic medical equipment field of biological existence supporting industries, lack of technical standards, as well as foreign companies extrusion problems. He told reporters that can be expected, ten years biomedical industrial concentration is more and more, leading to large enterprises, government should provide better services, create public research and development platform and enhance competitiveness.
Now, government departments in biomedical industries have been aware of the important significance of local economic development, and have corresponding preferential policies.
According to the shenzhen trade and industry and information commission, to the reporter stakeholders, the city will be Internet, new energy and biological medicine and other emerging industry funds to the development of 10 billion us dollars. "Soon, the first batch of 35 biomedical support program will be agreed."
No comments:
Post a Comment